ENGN enGene: מכפיל P/S עתידי

enGene Holdings Inc. is developing an innovative non-viral DNA delivery system, ensuring premium pricing in a niche market. The uniqueness of the local platform protects scientific developments from replication in the gene therapy race. Patent protection for dMGA and stringent FDA oversight create significant barriers to entry for competitors. The forward P/S multiple illustrates the valuation trend, where determines this specific parameter level.
ENGN (engene.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Forward P/S is calculated as the ratio of current market capitalization to expected annual revenue, measuring the premium the market is willing to pay for every dollar of projected sales. For enGene Holdings Inc. (ENGN), the volatility of the forward P/S chart reflects the valuation's sensitivity to engineering production complexities and FDA verdicts, turning this indicator into a barometer of confidence in the implementation of therapeutic systems.